drug
aprocitentan
Marketedupdated 3mo agoby Idorsia Pharmaceuticals US Inc
Approvedcommunity read0 votes
indications
investigational
Hypertension
all catalysts(0)
nothing on the calendar yet
Trials studying aprocitentan
Patent cliff
source: FDA Orange Bookfirst barrier falls
Mar 22, 2029
~2.6 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (6)
- Jul 26, 2038method-of-use (U-3878)US 11680058
- Mar 2, 2038method-of-use (U-3877)US 11787782
- Feb 26, 2038compositionUS 10919881
- Feb 26, 2038formulationUS 12297189
- Nov 6, 2037method-of-use (U-3879)US 11174247
- Sep 21, 2029compositionUS 83242323.1y
FDA exclusivities (1)
- Mar 22, 2029NCENew Chemical Entity (5y)2.6y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 38m ago
Found something off?
comments(0)
5-min edit window · permanent after that